NATALIE MARSHALL M.D.
Prescription History 1366445470
Internal Medicine - Medical Oncology in Berkeley, CA

NPI Status: Active since May 23, 2005

Contact Information

3100 SAN PABLO AVE.
SUITE 430
BERKELEY, CA
ZIP 94702
Phone: (510) 420-8000
Fax: (510) 985-5202

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for NATALIE MARSHALL M.D., an active Medical Oncology specialist practicing in Berkeley, CA. Our medical registry currently tracks 13 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 684 documented patient claims. Among these therapy options, the most frequently utilized medication is Letrozole, which accounts for 265 claims alone.


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 28
30-Day Fills 78.5
Days Supply 2,353
CA State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills138.0
Peer Average Days Supply4,109
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.7% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $452.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.16

State Avg Cost Per Claim

$12.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 50
30-Day Fills 138.0
Days Supply 4,140
CA State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills165.7
Peer Average Days Supply4,950
Conservative Utilization

This provider writes prescriptions for this formulation 26.5% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,828.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.56

State Avg Cost Per Claim

$27.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 231
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills36.0
Peer Average Days Supply559
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $356.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.76

State Avg Cost Per Claim

$19.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Exemestane

Generic Formulation: ExemestaneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 48.0
Days Supply 1,440
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills59.9
Peer Average Days Supply1,785
Conservative Utilization

This provider writes prescriptions for this formulation 40.7% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,439.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$152.50

State Avg Cost Per Claim

$259.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Gabapentin

Generic Formulation: GabapentinSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 70.5
Days Supply 2,115
CA State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills134.7
Peer Average Days Supply3,929
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.8% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $828.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.66

State Avg Cost Per Claim

$21.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Kisqali

Generic Formulation: Ribociclib SuccinateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 476
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.6
Peer Average Days Supply457
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $260,283.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,310.78

State Avg Cost Per Claim

$14,551.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ribociclib is used to treat breast cancer. It works by slowing or stopping the growth of cancer cells.

Letrozole

Generic Formulation: LetrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 265
30-Day Fills 719.7
Days Supply 21,571
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills111.8
Peer Average Days Supply3,337
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 452.1% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,236.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.63

State Avg Cost Per Claim

$32.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Lynparza

Generic Formulation: OlaparibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 22.0
Days Supply 660
CA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.5
Peer Average Days Supply553
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $231,710.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,033.84

State Avg Cost Per Claim

$13,776.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as breast, ovarian, fallopian tube, pancreatic, peritoneal cancer, prostate). Olaparib works by slowing or stopping the growth of cancer cells.

Olanzapine

Generic Formulation: OlanzapineSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 28
30-Day Fills 33.0
Days Supply 990
CA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills64.7
Peer Average Days Supply1,766
Conservative Utilization

This provider writes prescriptions for this formulation 48.1% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $846.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.22

State Avg Cost Per Claim

$41.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.

Therapeutic Applications

Olanzapine is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder). It may also be used in combination with other medication to treat depression. This medication can help to decrease hallucinations and help you to think more clearly and positively about yourself, feel less agitated, and take a more active part in everyday life. Olanzapine belongs to a class of drugs called atypical antipsychotics. It works by helping to restore the balance of certain natural substances in the brain. Talk to the doctor about the risks and benefits of treatment (especially when used by teenagers). See also Precautions section.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 348
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply570
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $284.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.81

State Avg Cost Per Claim

$8.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Orserdu

Generic Formulation: Elacestrant HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
CA State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$22,009.59

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Tagrisso

Generic Formulation: Osimertinib MesylateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills32.4
Peer Average Days Supply969
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.6% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $169,486.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,407.85

State Avg Cost Per Claim

$16,956.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 153
30-Day Fills 425.0
Days Supply 12,730
CA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills83.0
Peer Average Days Supply2,479
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 350.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,430.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.49

State Avg Cost Per Claim

$36.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like NATALIE MARSHALL M.D. provides transparency into local medical care patterns within Berkeley, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.